These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 27541661)

  • 1. Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?
    Vannini L; Muro A; Sanchis J; Ortiz-Pérez JT; Flores Umanzor E; López-Lereu MP; Badimon L; Sabaté M; Brugaletta S
    Int J Cardiol; 2016 Nov; 223():226-227. PubMed ID: 27541661
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study.
    Janssens GN; van Leeuwen MAH; van der Hoeven NW; de Waard GA; Nijveldt R; Diletti R; Zijlstra F; von Birgelen C; Escaned J; Valgimigli M; van Royen N
    J Cardiovasc Transl Res; 2016 Jun; 9(3):249-256. PubMed ID: 27102290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary use of P2Y
    Rakowski T; Siudak Z; Dziewierz A; Plens K; Kleczyński P; Dudek D
    J Thromb Thrombolysis; 2018 Jan; 45(1):151-157. PubMed ID: 29075924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction.
    Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F
    J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translation of experimental cardioprotective capability of P2Y
    Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
    Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
    J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
    Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
    Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
    Guimarães PO; Tricoci P
    Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?
    Alexopoulos D; Moulias A; Kanakakis I; Xanthopoulou I
    Int J Cardiol; 2015 Sep; 194():41-3. PubMed ID: 26011263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
    Khan N; Cox AR; Cotton JM
    Thromb Res; 2016 Jul; 143():141-8. PubMed ID: 27259210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Dillinger JG; Saeed A; Spagnoli V; Sollier CB; Sideris G; Silberman SM; Voicu S; Drouet L; Henry P
    Thromb Res; 2016 Aug; 144():56-61. PubMed ID: 27289074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radionuclide imaging of jeopardized myocardium: From the beginning of the race to the finish line.
    Gaudieri V; Nappi C; Petretta M
    J Nucl Cardiol; 2021 Aug; 28(4):1435-1437. PubMed ID: 31549289
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor.
    Wiessman M; Kheifets M; Schamroth Pravda N; Leshem Lev D; Ziv E; Kornowski R; Spectre G; Perl L
    J Thromb Thrombolysis; 2023 Apr; 55(3):407-414. PubMed ID: 36598739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.